Sanofi (SNY)
Healthcare · NMS
Price as at 1 Oct 2026, 02:38 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Sanofi trades at $41.23, which is 17% above the $34.40 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 68 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 19.6 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
SNY dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $2.42 | 1 |
| 2025 | $2.21 | 1 |
| 2024 | $2.04 | 1 |
| 2023 | $1.90 | 1 |
| 2022 | $2.04 | 2 |
| 2021 | $1.91 | 1 |
| 2020 | $1.75 | 1 |
| 2019 | $1.74 | 1 |
| 2018 | $1.86 | 1 |
| 2017 | $1.58 | 1 |
| 2016 | $1.63 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
SNY earnings and analyst estimates
Recommendation mix, 10 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
SNY passes 4 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
13 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Dodge & Cox, DODGE & COX$1.20B · 0.6% of book
- Ken Fisher, Fisher Asset Management, LLC$453.35M · 0.1% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$159.03M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$79.02M · 0.0% of book
- Capital Research Global, Capital Research Global Investors$71.56M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in SNY
Trades in SNY disclosed by members of Congress and executive-branch officials, latest first:
- Alan Armstrong · SenateBuy · $15,001 - $50,000 · traded 30 Mar 2026 · disclosed 21 Jul 2026
- Daniel Goldman · HouseSell · $15,001 - $50,000 · traded 10 Jul 2023 · disclosed 13 Aug 2023
- Daniel Goldman · HouseSell · $1,001 - $15,000 · traded 27 Feb 2023 · disclosed 20 Mar 2023
- Earl Blumenauer · HouseBuy · $15,001 - $50,000 · traded 27 May 2022 · disclosed 6 Jul 2022
- Greg Gianforte · HouseBuy · $1,001 - $15,000 · traded 19 Mar 2020 · disclosed 7 Apr 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
SNY peers
The largest companies in the same industry (Drug Manufacturers - General), then in the same sector.
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- NVSEF Novartis AG
- AZN.L AstraZeneca PLC
- NVO Novo Nordisk A/S
- PFE Pfizer Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Sanofi (SNY) undervalued?
Against our fair value estimate of $34.40, SNY at $41.23 is 17% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own SNY?
13 of the institutions we track reported a position in SNY in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is SNY's P/E ratio?
SNY trades at 19.6 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Sanofi (SNY) pay a dividend?
Yes. Sanofi yields 5.56% at the current share price. It has paid $2.42 per share over the trailing twelve months. It has paid a dividend in each of the last 23 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its SNY data?
Fundamentals for SNY come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:38 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for SNY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.